HCN2 Blocking Peptide (#BLP-PC030) is the original antigen used for immunization during Anti-HCN2 Antibody (#APC-030) generation. The blocking peptide binds and ‘blocks’ Anti-HCN2 primary antibody, this makes it a good negative reagent control to help confirm antibody specificity in western blot and immunohistochemistry applications. This control is also often called a pre-adsorption control.
- Western blot analysis of rat brain membranes:
- Expression of HCN2 in rat cerebellumImmunochistochemical staining of rat cerebellum frozen sections using Anti-HCN2 Antibody (#APC-030 ). A. HCN2 (red) appears in Purkinje cells (arrows). B. Staining of astrocytes with mouse anti-glial fibrillary acidic protein (GFAP, green demonstrates the restriction of HCN2 to neuronal cell bodies. C. Confocal merge of HCN2 and GFAP images demonstrates the respective localization of these proteins.
- Expression of HCN2 in mouse hypothalamusImmunohistochemical staining of mouse hypothalamus using Anti-HCN2 Antibody (#APC-030). A. HCN2 (red) appears in cells of the paraventricular nucleus (PVN, arrows). B. Staining of paraventricular nerve cells with mouse anti-calcium binding protein (CBD28k, green). C. Confocal merge of HCN2 and CBD28k demonstrates some co-localization. V = Third ventricle.
- Colocalization of HCN4 and HCN2 in mouse thalamusImmunohistochemical staining of mouse thalamus frozen section using Guinea pig Anti-HCN4 Antibody (#APC-052-GP) and rabbit Anti-HCN2 Antibody (#APC-030). A. Staining of HCN4 (green) appears in the ventral posterior thalamic nucleus (VPL). B. In the same section as in A, staining of HCN2 (red) appears in the ventral posterior thalamic nucleus (VPL) and also in the reticular thalamic nucleus (RT). The area between these thalamic nuclei (star) is white matter and neither protein is expressed in that region. C. Merged images of A and B.
- (C)EEAGPAGEPRGSQAS, corresponding to amino acid residues 147-161 of human HCN2 (Accession Q9UL51).